

Bob S Carter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4112725/publications.pdf>

Version: 2024-02-01

284
papers

26,506
citations

8159

76
h-index

6818

155
g-index

287
all docs

287
docs citations

287
times ranked

30154
citing authors

#	ARTICLE	IF	CITATIONS
1	5-Aminolevulinic acid for enhanced surgical visualization of high-grade gliomas: a prospective, multicenter study. <i>Journal of Neurosurgery</i> , 2022, 136, 1525-1534.	0.9	16
2	Multielectrode Spectroscopy Enables Rapid and Sensitive Molecular Profiling of Extracellular Vesicles. <i>ACS Central Science</i> , 2022, 8, 110-117.	5.3	12
3	Letter to the Editor. Cell therapy for Parkinson's disease. <i>Journal of Neurosurgery</i> , 2022, 136, 1810-1811.	0.9	1
4	Engineering Our Future: Advancing Cell and Gene Therapy in Neurosurgery. <i>Neurosurgery</i> , 2022, 68, 11-16.	0.6	0
5	Impaired neurogenesis alters brain biomechanics in a neuroprogenitor-based genetic subtype of congenital hydrocephalus. <i>Nature Neuroscience</i> , 2022, 25, 458-473.	7.1	46
6	Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression. <i>Nature Immunology</i> , 2022, 23, 971-984.	7.0	79
7	Abstract 5175: Novel approach for glioblastoma characterization via tumor specific extracellular vesicles. <i>Cancer Research</i> , 2022, 82, 5175-5175.	0.4	0
8	Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition. <i>Cancer Immunology Research</i> , 2022, 10, 996-1012.	1.6	18
9	<i>TERT</i> Promoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas. <i>Clinical Cancer Research</i> , 2021, 27, 169-178.	3.2	50
10	A rapid genotyping panel for detection of primary central nervous system lymphoma. <i>Blood</i> , 2021, 138, 382-386.	0.6	13
11	Blood-Based Detection of BRAF V600E in Gliomas and Brain Tumor Metastasis. <i>Cancers</i> , 2021, 13, 1227.	1.7	9
12	Commentary: Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment. <i>Neurosurgery</i> , 2021, 89, E68-E69.	0.6	1
13	An integrated magneto-electrochemical device for the rapid profiling of tumour extracellular vesicles from blood plasma. <i>Nature Biomedical Engineering</i> , 2021, 5, 678-689.	11.6	90
14	Intraoperative thalamocortical tract monitoring via direct cortical recordings during craniotomy. <i>Clinical Neurophysiology</i> , 2021, 132, 1416-1432.	0.7	6
15	Clinical outcomes as a function of the number of samples taken during stereotactic needle biopsies: a meta-analysis. <i>Journal of Neuro-Oncology</i> , 2021, 154, 1-11.	1.4	7
16	Abstract 456: Liquid biopsy for patient stratification and monitoring of dacomitinib clinical trial in patients with EGFR amplified recurrent glioblastoma. , 2021, , .		0
17	A Crowdsourced Consensus on Supratotal Resection Versus Gross Total Resection for Anatomically Distinct Primary Glioblastoma. <i>Neurosurgery</i> , 2021, 89, 712-719.	0.6	19
18	OMRT-2. Liquid biopsy for patient stratification and monitoring of dacomitinib clinical trial in patients with EGFR amplified recurrent glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, ii7-ii7.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Predicting Discharge Disposition Following Meningioma Resection Using a Multi-Institutional Natural Language Processing Model. <i>Neurosurgery</i> , 2021, 88, 838-845.	0.6	7
20	The role of extracellular vesicles in acquisition of resistance to therapy in glioblastomas. , 2021, 4, 1-16.		8
21	BIOM-12. DEVELOPMENT OF 5-ALA BASED LIQUID BIOPSY FOR THE NON-INVASIVE DIAGNOSIS OF GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi12-vi12.	0.6	0
22	BIOM-45. CHARACTERIZATION OF EVs RELEASED FROM 5-ALA DOSED GLIAL AND EXTRA-AXIAL TUMORS. <i>Neuro-Oncology</i> , 2021, 23, vi21-vi21.	0.6	0
23	Columnar Injection for Intracerebral Cell Therapy. <i>Operative Neurosurgery</i> , 2020, 18, 321-328.	0.4	7
24	Large and small extracellular vesicles released by glioma cells <i>in vitro</i> and <i>in vivo</i> . <i>Journal of Extracellular Vesicles</i> , 2020, 9, 1689784.	5.5	57
25	Radiation-induced extracellular vesicle (EV) release of miR-603 promotes IGF1-mediated stem cell state in glioblastomas. <i>EBioMedicine</i> , 2020, 55, 102736.	2.7	35
26	Orally Administered 5-aminolevulinic Acid for Isolation and Characterization of Circulating Tumor-Derived Extracellular Vesicles in Glioblastoma Patients. <i>Cancers</i> , 2020, 12, 3297.	1.7	10
27	American Neurotology Society, American Otological Society, and American Academy of Otolaryngology – Head and Neck Foundation Guide to Enhance Otologic and Neurotologic Care During the COVID-19 Pandemic. <i>Otology and Neurotology</i> , 2020, 41, 1163-1174.	0.7	17
28	Toward a Personalized Approach to Parkinson's Cell Therapy. <i>Movement Disorders</i> , 2020, 35, 2119-2120.	2.2	4
29	Novel Gene Fusions in Glioblastoma Tumor Tissue and Matched Patient Plasma. <i>Cancers</i> , 2020, 12, 1219.	1.7	11
30	Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1926-1932.	13.9	298
31	Liquid Biopsy Strategies to Distinguish Progression from Pseudoprogression and Radiation Necrosis in Glioblastomas. <i>Advanced Biology</i> , 2020, 4, 2000029.	3.0	12
32	Airborne Aerosol Generation During Endonasal Procedures in the Era of COVID-19: Risks and Recommendations. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 163, 465-470.	1.1	118
33	Glioblastomas located in proximity to the subventricular zone (SVZ) exhibited enrichment of gene expression profiles associated with the cancer stem cell state. <i>Journal of Neuro-Oncology</i> , 2020, 148, 455-462.	1.4	24
34	FASN Is a Biomarker Enriched in Malignant Glioma-Derived Extracellular Vesicles. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1931.	1.8	20
35	Endonasal instrumentation and aerosolization risk in the era of COVID-19: simulation, literature review, and proposed mitigation strategies. <i>International Forum of Allergy and Rhinology</i> , 2020, 10, 798-805.	1.5	284
36	From laboratory to clinic: Translation of extracellular vesicle based cancer biomarkers. <i>Methods</i> , 2020, 177, 58-66.	1.9	55

#	ARTICLE	IF	CITATIONS
37	Letter: Adaptation Under Fire: Two Harvard Neurosurgical Services During the COVID-19 Pandemic. <i>Neurosurgery</i> , 2020, 87, E173-E177.	0.6	30
38	Human autologous iPSC-derived dopaminergic progenitors restore motor function in Parkinson's disease models. <i>Journal of Clinical Investigation</i> , 2020, 130, 904-920.	3.9	102
39	Receptor tyrosine kinase gene amplification is predictive of intraoperative seizures during glioma resection with functional mapping. <i>Journal of Neurosurgery</i> , 2020, 132, 1017-1023.	0.9	5
40	Multimodal cerebral arteriovenous malformation treatment: a 12-year experience and comparison of key outcomes to ARUBA. <i>Journal of Neurosurgery</i> , 2020, 133, 1792-1801.	0.9	18
41	Editorial. COVID-19 and academic neurosurgery. <i>Journal of Neurosurgery</i> , 2020, 133, 8-9.	0.9	20
42	Editorial. COVID-19 and neurosurgical practice: an interim report. <i>Journal of Neurosurgery</i> , 2020, 133, 3-4.	0.9	19
43	Predicting Discharge Disposition Following Meningioma Resection Using a Multiinstitutional Natural Language Processing Model. , 2020, 81, .		0
44	SURG-21. A CROWDSOURCED CONSENSUS ON SUPRATOTAL RESECTION VERSUS GROSS TOTAL RESECTION FOR ANATOMICALLY DISTINCT PRIMARY GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii207-ii208.	0.6	0
45	STEM-24. RADIATION-INDUCED EXTRACELLULAR VESICLE (EV) RELEASE OF miR-603 PROMOTES IGF1-MEDIATED STEM CELL STATE IN GLIOBLASTOMAS. <i>Neuro-Oncology</i> , 2020, 22, ii201-ii201.	0.6	0
46	Assessing the Understandability and Actionability of Online Neurosurgical Patient Education Materials. <i>World Neurosurgery</i> , 2019, 130, e588-e597.	0.7	29
47	An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. <i>Cell</i> , 2019, 178, 835-849.e21.	13.5	1,408
48	A Pilot Proof-Of-Principle Analysis Demonstrating Dielectrophoresis (DEP) as a Glioblastoma Biomarker Platform. <i>Scientific Reports</i> , 2019, 9, 10279.	1.6	27
49	CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. <i>Nature Biotechnology</i> , 2019, 37, 1049-1058.	9.4	347
50	Commentary: Predicting Inpatient Length of Stay After Brain Tumor Surgery: Developing Machine Learning Ensembles to Improve Predictive Performance. <i>Neurosurgery</i> , 2019, 85, E444-E445.	0.6	1
51	Smoking As a Risk Factor for Postcraniotomy 30-Day Mortality. <i>World Neurosurgery</i> , 2019, 127, e400-e406.	0.7	1
52	Factors that modify the risk of intraoperative seizures triggered by electrical stimulation during supratentorial functional mapping. <i>Clinical Neurophysiology</i> , 2019, 130, 1058-1065.	0.7	22
53	Navigating the Landscape of Tumor Extracellular Vesicle Heterogeneity. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1349.	1.8	39
54	The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research. <i>Cell</i> , 2019, 177, 231-242.	13.5	152

#	ARTICLE	IF	CITATIONS
55	Correlation Structure in Micro-ECoG Recordings is Described by Spatially Coherent Components. <i>PLoS Computational Biology</i> , 2019, 15, e1006769.	1.5	32
56	CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. , 2019, 7, 304.		181
57	Characterization of plasma-derived protoporphyrin-IX-positive extracellular vesicles following 5-ALA use in patients with malignant glioma. <i>EBioMedicine</i> , 2019, 48, 23-35.	2.7	27
58	The Impact of Unmet Communication and Education Needs on Neurosurgical Patient and Caregiver Experiences of Care: A Qualitative Exploratory Analysis. <i>World Neurosurgery</i> , 2019, 122, e1528-e1535.	0.7	8
59	Is the new ASNM intraoperative neuromonitoring supervision "guideline" a trustworthy guideline? A commentary. <i>Journal of Clinical Monitoring and Computing</i> , 2019, 33, 185-190.	0.7	3
60	Prognostic Importance of Age, Tumor Location, and Tumor Grade in Grade II Astrocytomas: An Integrated Analysis of the Cancer Genome Atlas and the Surveillance, Epidemiology, and End Results Database. <i>World Neurosurgery</i> , 2019, 121, e411-e418.	0.7	10
61	Tentorial sling for microvascular decompression in patients with trigeminal neuralgia: a description of operative technique and clinical outcomes. <i>Journal of Neurosurgery</i> , 2019, 130, 1315-1320.	0.9	40
62	Extracellular Vesicles in Glioblastoma Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2019, 10, 3137.	2.2	88
63	Abstract LB-066: BiTE-armed CARs overcome antigen escape in EGFRvIII-targeted therapy for glioblastoma. <i>Cancer Research</i> , 2019, 79, LB-066-LB-066.	0.4	4
64	Role of Biopsies in the Management of Intracranial Gliomas. <i>Progress in Neurological Surgery</i> , 2018, 30, 232-243.	1.3	12
65	Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. <i>Science Advances</i> , 2018, 4, eaar2766.	4.7	416
66	Sub-millimeter ECoG pitch in human enables higher fidelity cognitive neural state estimation. <i>NeuroImage</i> , 2018, 176, 454-464.	2.1	36
67	Mapping of genomic EGFRvIII deletions in glioblastoma: insight into rearrangement mechanisms and biomarker development. <i>Neuro-Oncology</i> , 2018, 20, 1310-1320.	0.6	27
68	Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects. <i>Progress in Neurobiology</i> , 2018, 168, 1-20.	2.8	84
69	Quantification of glioblastoma mass effect by lateral ventricle displacement. <i>Scientific Reports</i> , 2018, 8, 2827.	1.6	23
70	Post-operative imaging assessment of non-functioning pituitary adenomas. <i>Acta Neurochirurgica</i> , 2018, 160, 1029-1039.	0.9	4
71	Intraoperative Magnetic Resonance Imaging-Guided Biopsy in the Diagnosis of Suprasellar Langerhans Cell Histiocytosis. <i>World Neurosurgery</i> , 2018, 112, 6-13.	0.7	6
72	Interaction Between the Contributions of Tumor Location, Tumor Grade, and Patient Age to the Survival Benefit Associated with Gross Total Resection. <i>World Neurosurgery</i> , 2018, 111, e790-e798.	0.7	11

#	ARTICLE	IF	CITATIONS
73	Engineered nanointerfaces for microfluidic isolation and molecular profiling of tumor-specific extracellular vesicles. <i>Nature Communications</i> , 2018, 9, 175.	5.8	248
74	Development and Translation of PEDOT:PSS Microelectrodes for Intraoperative Monitoring. <i>Advanced Functional Materials</i> , 2018, 28, 1700232.	7.8	97
75	Oligodendroglioma resection: a Surveillance, Epidemiology, and End Results (SEER) analysis. <i>Journal of Neurosurgery</i> , 2018, 128, 1076-1083.	0.9	38
76	Risk Factors for Readmission with Cerebrospinal Fluid Leakage Within 30 Days of Vestibular Schwannoma Surgery. <i>Neurosurgery</i> , 2018, 82, 630-637.	0.6	20
77	Superior Prognostic Value of Cumulative Intracranial Tumor Volume Relative to Largest Intracranial Tumor Volume for Stereotactic Radiosurgery-Treated Brain Metastasis Patients. <i>Neurosurgery</i> , 2018, 82, 473-480.	0.6	23
78	Detection of glioblastoma in biofluids. <i>Journal of Neurosurgery</i> , 2018, 129, 334-340.	0.9	40
79	Survival patterns of oligoastrocytoma patients: A surveillance, epidemiology and end results (SEER) based analysis. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2018, 11, 70-75.	0.2	3
80	Impact of neurosurgeon specialization on patient outcomes for intracranial and spinal surgery: a retrospective analysis of the Nationwide Inpatient Sample 1998-2009. <i>Journal of Neurosurgery</i> , 2018, 128, 1578-1588.	0.9	15
81	ATIM-26. IMMUNOLOGIC TRENDS ASSOCIATED WITH PATIENT OUTCOMES IN A PHASE 1 CLINICAL TRIAL OF TOCA 511 AND TOCA FC IN RECURRENT HIGH GRADE GLIOMA. <i>Neuro-Oncology</i> , 2018, 20, vi6-vi7.	0.6	1
82	NIMG-25. MOLECULAR PHYSIOLOGY OF CONTRAST ENHANCEMENT IN GLIOBLASTOMAS: AN ANALYSIS OF THE CANCER IMAGING ARCHIVE (TCIA). <i>Neuro-Oncology</i> , 2018, 20, vi181-vi181.	0.6	0
83	SURG-04. SURVIVAL BENEFIT ASSOCIATED WITH GROSS TOTAL RESECTION IN GRADE II ASTROCYTOMAS: AN INTEGRATED ANALYSIS OF THE SEER AND TCGA DATABASE. <i>Neuro-Oncology</i> , 2018, 20, vi250-vi251.	0.6	0
84	RDNA-01. microRNA DEGRADATION MEDIATED GENETIC HETEROGENEITY AS A NOVEL MECHANISM FOR TEMOZOLOMIDE RESISTANCE IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi221-vi222.	0.6	0
85	309 Highly Sensitive Detection of the IDH1 R132H Mutation in the Plasma of Glioma Patients. <i>Neurosurgery</i> , 2018, 65, 125-126.	0.6	0
86	The role of proton beam therapy in central neurocytoma: A single-institution experience. <i>Practical Radiation Oncology</i> , 2018, 8, e305-e311.	1.1	1
87	Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons. <i>Neurosurgical Focus</i> , 2018, 44, E13.	1.0	25
88	Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. <i>Neuro-Oncology</i> , 2018, 20, 1383-1392.	0.6	135
89	Molecular physiology of contrast enhancement in glioblastomas: An analysis of The Cancer Imaging Archive (TCIA). <i>Journal of Clinical Neuroscience</i> , 2018, 55, 86-92.	0.8	14
90	Cumulative Intracranial Tumor Volume Augments the Prognostic Value of Diagnosis-Specific Graded Prognostic Assessment Model for Survival in Patients with Melanoma Cerebral Metastases. <i>Neurosurgery</i> , 2018, 83, 237-244.	0.6	21

#	ARTICLE	IF	CITATIONS
91	Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma. PLoS ONE, 2018, 13, e0199414.	1.1	30
92	Extracellular Vesicles as a Platform for Glioma Therapeutic Development. Progress in Neurological Surgery, 2018, 32, 172-179.	1.3	2
93	Blood-based biomarkers for the diagnosis and monitoring of gliomas. Neuro-Oncology, 2018, 20, 1155-1161.	0.6	67
94	Carotid artery stenting vs. carotid endarterectomy in the management of carotid artery stenosis: Lessons learned from randomized controlled trials. , 2018, 9, 85.		14
95	Abstract A085: Durable responses observed in recurrent high-grade glioma (rHGG) with Toca 511 and Toca FC treatment. , 2018, , .		0
96	Abstract 1956: miR-181d degradation mediated genetic heterogeneity and acquired resistance. , 2018, , .		1
97	Defining Glioblastoma Resectability Through the Wisdom of the Crowd: A Proof-of-Principle Study. Neurosurgery, 2017, 80, 590-601.	0.6	34
98	Editorial: Health care reform and the uninsured: lessons from Massachusetts. Journal of Neurosurgery, 2017, 126, 165-166.	0.9	0
99	Editorial: Acute stress impacts psychomotor performance. Journal of Neurosurgery, 2017, 126, 69-70.	0.9	1
100	Clinical efficacy and safety of surface imaging guided radiosurgery (SIG-RS) in the treatment of benign skull base tumors. Journal of Neuro-Oncology, 2017, 132, 307-312.	1.4	22
101	Editorial. Nimodipine treatment. Journal of Neurosurgery, 2017, 127, 1374-1375.	0.9	1
102	Survival trends of oligodendroglial tumor patients and associated clinical practice patterns: a SEER-based analysis. Journal of Neuro-Oncology, 2017, 133, 173-181.	1.4	14
103	Effect of Gross Total Resection in World Health Organization Grade II Astrocytomas: SEER-Based Survival Analysis. World Neurosurgery, 2017, 103, 741-747.	0.7	11
104	Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients. Neuro-Oncology, 2017, 19, 1494-1502.	0.6	168
105	Management and Survival Patterns of Patients with Gliomatosis Cerebri: A SEER-Based Analysis. World Neurosurgery, 2017, 103, 186-193.	0.7	13
106	Ipsilateral Pupillary Dilation Following Carotid Endarterectomy: A Temporary and Benign Phenomenon. Neurosurgery, 2017, 80, E239-E244.	0.6	2
107	Depression After Spinal Surgery: A Comparative Analysis of the California Outcomes Database. Mayo Clinic Proceedings, 2017, 92, 88-97.	1.4	25
108	Coding and noncoding landscape of extracellular RNA released by human glioma stem cells. Nature Communications, 2017, 8, 1145.	5.8	384

#	ARTICLE	IF	CITATIONS
109	The use of TMZ embedded hydrogels for the treatment of orthotopic human glioma xenografts. <i>Journal of Clinical Neuroscience</i> , 2017, 45, 288-292.	0.8	6
110	Liquid biopsy for brain tumors. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 943-947.	1.5	113
111	Analysis of extracellular RNA in cerebrospinal fluid. <i>Journal of Extracellular Vesicles</i> , 2017, 6, 1317577.	5.5	68
112	Survival Patterns of 5750 Stereotactic Radiosurgery-Treated Patients with Brain Metastasis as a Function of the Number of Lesions. <i>World Neurosurgery</i> , 2017, 107, 944-951.e1.	0.7	30
113	Improving the Prognostic Value of Disease-Specific Graded Prognostic Assessment Model for Renal Cell Carcinoma by Incorporation of Cumulative Intracranial Tumor Volume. <i>World Neurosurgery</i> , 2017, 108, 151-156.	0.7	24
114	Real-time Magnetic Resonance Imaging-Guided Biopsy Using SmartFrame® Stereotaxis in the Setting of a Conventional Diagnostic Magnetic Resonance Imaging Suite. <i>Operative Neurosurgery</i> , 2017, 13, 329-337.	0.4	14
115	Introduction. Neurosurgical rehabilitation. <i>Neurosurgical Focus</i> , 2017, 43, E1.	1.0	0
116	Establishing reconstructive neurosurgery as a subspecialty. <i>Neurosurgical Focus</i> , 2017, 43, E7.	1.0	8
117	Rapid Isolation and Detection of Exosomes and Associated Biomarkers from Plasma. <i>ACS Nano</i> , 2017, 11, 6641-6651.	7.3	275
118	The Association between Psychiatric Comorbidities and Outcomes for Inpatients with Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2017, 34, 1005-1016.	1.7	22
119	A cerebrospinal fluid microRNA signature as biomarker for glioblastoma. <i>Oncotarget</i> , 2017, 8, 68769-68779.	0.8	111
120	Durable complete responses observed in IDH1 mutated high grade glioma at first recurrence undergoing treatment with Toca 511 and Toca FC.. <i>Journal of Clinical Oncology</i> , 2017, 35, e13504-e13504.	0.8	1
121	Abstract LB-207: PI3K ^{Î³} inhibition suppresses glioblastoma tumorigenicity through disruption of an IL11-STAT3-MYC signaling axis between microglia and glioblastoma. , 2017, , .		0
122	Early Detection of Glioblastoma. , 2016, , 247-252.		0
123	Differential localization of glioblastoma subtype: implications on glioblastoma pathogenesis. <i>Oncotarget</i> , 2016, 7, 24899-24907.	0.8	27
124	Characterization and Correction of Geometric Distortions in 814 Diffusion Weighted Images. <i>PLoS ONE</i> , 2016, 11, e0152472.	1.1	116
125	Impact of medical academic genealogy on publication patterns: An analysis of the literature for surgical resection in brain tumor patients. <i>Annals of Neurology</i> , 2016, 79, 169-177.	2.8	20
126	Cumulative Intracranial Tumor Volume (CITV) Enhances the Prognostic Value of the Lung-Specific Graded Prognostic Assessment (GPA) Model. <i>Neurosurgery</i> , 2016, 79, 246-252.	0.6	22

#	ARTICLE	IF	CITATIONS
127	Journal Bias™ in peer-reviewed literature: an analysis of the surgical high-grade glioma literature. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1248-1250.	0.9	5
128	Optimizing preservation of extracellular vesicular miRNAs derived from clinical cerebrospinal fluid. <i>Cancer Biomarkers</i> , 2016, 17, 125-132.	0.8	74
129	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Posttreatment Follow-up Evaluation of Patients With Nonfunctioning Pituitary Adenomas. <i>Neurosurgery</i> , 2016, 79, E541-E543.	0.6	34
130	Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 3, 63-72.	1.2	255
131	Increased Operative Time for Benign Cranial Nerve Tumor Resection Correlates with Increased Morbidity Postoperatively. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2016, 77, 350-357.	0.4	19
132	Coevolution of Peer-Reviewed Literature and Clinical Practice in High-Grade Glioma Resection. <i>World Neurosurgery</i> , 2016, 96, 237-241.	0.7	4
133	Predictors of 30-day perioperative morbidity and mortality of unruptured intracranial aneurysm surgery. <i>Clinical Neurology and Neurosurgery</i> , 2016, 149, 75-80.	0.6	31
134	A pilot study of physician personal preferences for treatment of glioblastoma. <i>Acta Neurochirurgica</i> , 2016, 158, 1933-1933.	0.9	0
135	Histologic Evidence for Arteriovenous Malformation-Like Vasculature Occurring within an Intracerebral Schwannoma: A Case Report and Review of the Literature. <i>World Neurosurgery</i> , 2016, 92, 582.e9-582.e13.	0.7	4
136	Morbid obesity increases risk of morbidity and reoperation in resection of benign cranial nerve neoplasms. <i>Clinical Neurology and Neurosurgery</i> , 2016, 148, 105-109.	0.6	16
137	Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. <i>Science Translational Medicine</i> , 2016, 8, 341ra75.	5.8	158
138	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Preoperative Imaging Assessment of Patients With Suspected Nonfunctioning Pituitary Adenomas. <i>Neurosurgery</i> , 2016, 79, E524-E526.	0.6	20
139	Future directions of operative neuro-oncology. <i>Journal of Neuro-Oncology</i> , 2016, 130, 377-382.	1.4	5
140	Is Patient Age Associated with Perioperative Outcomes After Surgical Resection of Benign Cranial Nerve Neoplasms?. <i>World Neurosurgery</i> , 2016, 89, 101-107.	0.7	18
141	Coma and Stroke Following Surgical Treatment of Unruptured Intracranial Aneurysm: An American College of Surgeons National Surgical Quality Improvement Program Study. <i>World Neurosurgery</i> , 2016, 91, 272-278.	0.7	16
142	Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase. <i>Clinical Cancer Research</i> , 2016, 22, 6256-6265.	3.2	43
143	A 22-Year Old Woman with Right Eyelid Swelling. <i>Brain Pathology</i> , 2016, 26, 425-426.	2.1	0
144	Superior Efficacy of Gross Total Resection in Anaplastic Astrocytoma Patients Relative to Glioblastoma Patients. <i>World Neurosurgery</i> , 2016, 90, 186-193.	0.7	13

#	ARTICLE	IF	CITATIONS
145	ExRNA in Biofluids as Biomarkers for Brain Tumors. Cellular and Molecular Neurobiology, 2016, 36, 353-360.	1.7	20
146	Stereotactic Radiosurgery Treatment of Trigeminal Neuralgia: Clinical Outcomes and Prognostic Factors. World Neurosurgery, 2016, 90, 604-612.e11.	0.7	24
147	Management patterns of patients with cerebral metastases who underwent multiple stereotactic radiosurgeries. Journal of Neuro-Oncology, 2016, 128, 119-128.	1.4	13
148	Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: A SEER-based analysis. Neuro-Oncology Practice, 2016, 3, 29-38.	1.0	22
149	Intraoperative magnetic resonance imaging assessment of non-functioning pituitary adenomas during transsphenoidal surgery. Pituitary, 2016, 19, 222-231.	1.6	22
150	Comparative Analysis of Technologies for Quantifying Extracellular Vesicles (EVs) in Clinical Cerebrospinal Fluids (CSF). PLoS ONE, 2016, 11, e0149866.	1.1	99
151	Meeting report: discussions and preliminary findings on extracellular RNA measurement methods from laboratories in the NIH Extracellular RNA Communication Consortium. Journal of Extracellular Vesicles, 2015, 4, 26533.	5.5	51
152	Extracellular RNAs: development as biomarkers of human disease. Journal of Extracellular Vesicles, 2015, 4, 27495.	5.5	72
153	Integration of extracellular RNA profiling data using metadata, biomedical ontologies and Linked Data technologies. Journal of Extracellular Vesicles, 2015, 4, 27497.	5.5	48
154	Thirty-Day Perioperative Outcomes in Spinal Fusion by Specialty Within the NSQIP Database. Spine, 2015, 40, 1122-1131.	1.0	60
155	Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition. Oncotarget, 2015, 6, 11751-11767.	0.8	9
156	Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion*. Journal of Biological Chemistry, 2015, 290, 14798-14809.	1.6	15
157	Extracellular vesicles, tissue factor, cancer and thrombosis – discussion themes of the ISEV 2014 Educational Day. Journal of Extracellular Vesicles, 2015, 4, 26901.	5.5	69
158	miRNA contents of cerebrospinal fluid extracellular vesicles in glioblastoma patients. Journal of Neuro-Oncology, 2015, 123, 205-216.	1.4	128
159	Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma. Nature Communications, 2015, 6, 6999.	5.8	484
160	Introduction: A focus on low-grade glioma. Neurosurgical Focus, 2015, 38, E2.	1.0	1
161	Treatment biases in traumatic neurosurgical care: a retrospective study of the Nationwide Inpatient Sample from 1998 to 2009. Journal of Neurosurgery, 2015, 123, 406-414.	0.9	25
162	Abstract 979: Dynamic epigenetic regulation of glioblastoma tumorigenicity through LSD1 modulation of MYC expression. , 2015, , .		1

#	ARTICLE	IF	CITATIONS
163	Arteriovenous malformation within an isocitrate dehydrogenase 1 mutated anaplastic oligodendroglioma. , 2015, 6, 295.		1
164	Abstract PR13: Epigenetic regulation of MYC drives dynamic transition between tumor initiating states in glioblastoma. , 2015, , .		0
165	Abstract PR02: Dynamic epigenetic regulation of glioblastoma tumorigenicity through a LSD1-MYC-OLIG2 axis. , 2015, , .		0
166	Informatic system for a global tissueâ€œfluid biorepository with a graph theoryâ€œoriented graphical user interface. Journal of Extracellular Vesicles, 2014, 3, 24247.	5.5	4
167	BM-08 * PROGNOSTIC FACTORS FOR SRS-TREATED PATIENTS WITH CEREBRAL METASTASIS: IMPLICATIONS ON RANDOMIZED CONTROL TRIAL DESIGN AND INTER-INSTITUTIONAL COLLABORATIVE EFFORTS. Neuro-Oncology, 2014, 16, v33-v33.	0.6	1
168	Gross-total resection outcomes in an elderly population with glioblastoma: a SEER-based analysis. Journal of Neurosurgery, 2014, 120, 31-39.	0.9	112
169	Recommendations for the Management of Cerebral and Cerebellar Infarction With Swelling. Stroke, 2014, 45, 1222-1238.	1.0	403
170	Long-term follow-up of unruptured intracranial aneurysms repaired in California. Journal of Neurosurgery, 2014, 120, 1349-1357.	0.9	36
171	72 Year Old Female with Leg Weakness. Brain Pathology, 2014, 24, 195-196.	2.1	0
172	The Cancer Genome Atlas expression profiles of low-grade gliomas. Neurosurgical Focus, 2014, 36, E23.	1.0	10
173	Hemicraniectomy in the management of malignant middle cerebral artery infarction: Lessons from randomized, controlled trials. , 2014, 5, 72.		7
174	Incidence and predictors of 30-day readmission for patients discharged home after craniotomy for malignant supratentorial tumors in California (1995â€œ2010). Journal of Neurosurgery, 2014, 120, 1201-1211.	0.9	77
175	Extracellular vesicles as a platform for â€œliquid biopsyâ€œ™ in glioblastoma patients. Expert Review of Molecular Diagnostics, 2014, 14, 819-825.	1.5	104
176	Diffusion-Weighted Imaging in Cancer: Physical Foundations and Applications of Restriction Spectrum Imaging. Cancer Research, 2014, 74, 4638-4652.	0.4	179
177	RNA-seq of 272 gliomas revealed a novel, recurrent <i>PTPRZ1-MET</i> fusion transcript in secondary glioblastomas. Genome Research, 2014, 24, 1765-1773.	2.4	316
178	Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study. Journal of Neuro-Oncology, 2014, 119, 361-368.	1.4	22
179	Glioblastoma Microvesicles Transport RNA and Proteins, Promoting Tumor Growth. Tumors of the Central Nervous System, 2014, , 101-112.	0.1	1
180	Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma. Oncotarget, 2014, 5, 882-893.	0.8	127

#	ARTICLE	IF	CITATIONS
181	A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas. <i>Oncotarget</i> , 2014, 5, 4026-4039.	0.8	62
182	Epigenetic suppression of EGFR signaling in G-CIMP+ glioblastomas. <i>Oncotarget</i> , 2014, 5, 7342-7356.	0.8	19
183	Abstract 2737: Modulation of mitotic DNA damage as a paradigm for glioblastoma therapy. , 2014, , .		0
184	Immediate post-operative brachytherapy prior to irradiation and temozolomide for newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2013, 113, 467-477.	1.4	28
185	Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. <i>Journal of Neuro-Oncology</i> , 2013, 113, 1-11.	1.4	1,054
186	150€f Gene Expression Analysis Revealed Distinct Physiology in G-CIMP+ and G-CIMP- Gliomas. <i>Neurosurgery</i> , 2013, 60, 169-170.	0.6	0
187	Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors. <i>Journal of Neurosurgery</i> , 2013, 118, 1183-1187.	0.9	59
188	Neurocognitive assessment following whole brain radiation therapy and radiosurgery for patients with cerebral metastases: TableÅ1. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1384-1391.	0.9	106
189	ONYX versus n-BCA for embolization of cranial dural arteriovenous fistulas. <i>Journal of NeuroInterventional Surgery</i> , 2013, 5, 306-310.	2.0	73
190	miR-21 in the Extracellular Vesicles (EVs) of Cerebrospinal Fluid (CSF): A Platform for Glioblastoma Biomarker Development. <i>PLoS ONE</i> , 2013, 8, e78115.	1.1	270
191	BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e109.	2.3	284
192	Introduction. <i>Neurosurgical Focus</i> , 2013, 34, Introduction.	1.0	15
193	Neuro-oncologic Applications of Exosomes, Microvesicles, and Other Nano-Sized Extracellular Particles. <i>Neurosurgery</i> , 2013, 72, 501-510.	0.6	35
194	78 Year Old Male with Dysphagia and Dysarthria. <i>Brain Pathology</i> , 2013, 23, 705-706.	2.1	0
195	Key concepts in glioblastoma therapy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 753-760.	0.9	69
196	Surgical Management of Intracerebral Hemorrhage. , 2012, , 823-836.		2
197	Viral vectors: promising new therapeutics in the battle against glioblastoma. <i>Expert Review of Clinical Pharmacology</i> , 2012, 5, 489-491.	1.3	0
198	Ventriculoperitoneal shunting versus endoscopic third ventriculostomy in the treatment of patients with hydrocephalus related to metastasis. , 2012, 3, 97.		25

#	ARTICLE	IF	CITATIONS
199	Frameless, Real-Time, Surface Imaging-Guided Radiosurgery. <i>Neurosurgery</i> , 2012, 71, 844-852.	0.6	56
200	Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. <i>Nature Medicine</i> , 2012, 18, 1835-1840.	15.2	647
201	Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor-Modified T Cells. <i>Clinical Cancer Research</i> , 2012, 18, 5949-5960.	3.2	124
202	CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy. <i>Journal of Neuro-Oncology</i> , 2012, 110, 37-48.	1.4	9
203	Post-transcriptional regulation of O6-methylguanine-DNA methyltransferase MGMT in glioblastomas. <i>Cancer Biomarkers</i> , 2012, 10, 185-193.	0.8	36
204	RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. <i>BMC Cancer</i> , 2012, 12, 22.	1.1	176
205	Genomic profiling of glioblastoma: convergence of fundamental biologic tenets and novel insights. <i>Journal of Neuro-Oncology</i> , 2012, 107, 1-12.	1.4	47
206	Recombinant adeno-associated virus type 2 pseudotypes: comparing safety, specificity, and transduction efficiency in the primate striatum. <i>Journal of Neurosurgery</i> , 2011, 114, 672-680.	0.9	18
207	A review of lumbar spinal instrumentation: evidence and controversy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 948-951.	0.9	16
208	DNA damage response and repair: insights into strategies for radiation sensitization of gliomas. <i>Future Oncology</i> , 2011, 7, 1335-1346.	1.1	34
209	Role of magnesium sulfate in aneurysmal subarachnoid hemorrhage management: A meta-analysis of controlled clinical trials. <i>Journal of Innovative Optical Health Sciences</i> , 2011, 6, 26-31.	0.5	15
210	Racial, Ethnic, and Socioeconomic Disparities in Patient Outcomes After Craniotomy for Tumor in Adult Patients in the United States, 1988-2004. <i>Neurosurgery</i> , 2010, 66, 427-438.	0.6	167
211	Microfluidic isolation and transcriptome analysis of serum microvesicles. <i>Lab on A Chip</i> , 2010, 10, 505-511.	3.1	462
212	Microsurgical Clip Obliteration of Middle Cerebral Aneurysm Using Intraoperative Flow Assessment. <i>Journal of Visualized Experiments</i> , 2009, , .	0.2	2
213	Effective Glycemic Control With Aggressive Hyperglycemia Management Is Associated With Improved Outcome in Aneurysmal Subarachnoid Hemorrhage. <i>Stroke</i> , 2009, 40, 1644-1652.	1.0	61
214	Genetically engineered T cells to target EGFRvIII expressing glioblastoma. <i>Journal of Neuro-Oncology</i> , 2009, 94, 373-382.	1.4	62
215	LONG-TERM RECURRENCE RATES OF ATYPICAL MENINGIOMAS AFTER GROSS TOTAL RESECTION WITH OR WITHOUT POSTOPERATIVE ADJUVANT RADIATION. <i>Neurosurgery</i> , 2009, 64, 56-60.	0.6	418
216	A New Era of Outcomes Research. <i>Neurosurgery</i> , 2009, 64, N15.	0.6	1

#	ARTICLE	IF	CITATIONS
217	Standard Operating Procedures. Neurosurgery, 2009, 64, N14.	0.6	0
218	Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nature Cell Biology, 2008, 10, 1470-1476.	4.6	4,285
219	Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2. Journal of Neurosurgery, 2008, 108, 979-988.	0.9	35
220	Surrogate Measures of Outcome in Clinical Trials. Neurosurgery, 2008, 63, N5.	0.6	1
221	Shunting for Alzheimer's Disease. Neurosurgery, 2008, 63, N11.	0.6	0
222	Wrong-site Surgery. Neurosurgery, 2008, 62, N7-N8.	0.6	0
223	ISAT Subgroups. Neurosurgery, 2008, 63, N14.	0.6	6
224	The Nationwide Inpatient Sample. Neurosurgery, 2008, 62, N9.	0.6	1
225	Clinical Equipoise and the Surgical Randomized Controlled Trial. Neurosurgery, 2008, 62, N9-N10.	0.6	6
226	Angiotensin-1 increases survival and reduces the development of lung edema induced by endotoxin administration in a murine model of acute lung injury. Critical Care Medicine, 2008, 36, 262-267.	0.4	47
227	INCREASED PREVALENCE OF OBESITY AND OBESITY-RELATED POSTOPERATIVE COMPLICATIONS IN MALE PATIENTS WITH MENINGIOMAS. Neurosurgery, 2007, 61, 754-761.	0.6	30
228	Outcomes studies in cerebrovascular neurosurgery. Neurosurgical Focus, 2007, 22, 1-15.	1.0	9
229	High-dose Bosentan in the Prevention and Treatment of Subarachnoid Hemorrhage-induced Cerebral Vasospasm: An Open-label Feasibility Study. Neurocritical Care, 2007, 7, 194-202.	1.2	10
230	Epidemiology of the Size Distribution of Intracranial Bifurcation Aneurysms: Smaller Size of Distal Aneurysms and Increasing Size of Unruptured Aneurysms with Age. Neurosurgery, 2006, 58, 217-223.	0.6	67
231	Noninvasive Bioluminescence Imaging of Luciferase Expressing Intracranial U87 Xenografts: Correlation with Magnetic Resonance Imaging Determined Tumor Volume and Longitudinal Use in Assessing Tumor Growth and Antiangiogenic Treatment Effect. Neurosurgery, 2006, 58, 365-372.	0.6	112
232	Chimeric T-cell Receptor Therapy for Glioblastoma Multiforme. Neurosurgery, 2006, 59, 486.	0.6	0
233	High Incidence of Obesity and Obesity-related Postoperative Complications in Male Patients with Meningiomas. Neurosurgery, 2006, 59, 487-488.	0.6	0
234	OUTCOMES FOR SURGICAL AND ENDOVASCULAR MANAGEMENT OF INTRACRANIAL ANEURYSMS USING A COMPREHENSIVE GRADING SYSTEM. Neurosurgery, 2006, 59, 1037-1043.	0.6	46

#	ARTICLE	IF	CITATIONS
235	Complications of Cerebral Arteriovenous Malformation Embolization: Multivariate Analysis of Predictive Factors. <i>Neurosurgery</i> , 2006, 58, 602-611.	0.6	163
236	Relationship between hyperglycemia and symptomatic vasospasm after subarachnoid hemorrhage*. <i>Critical Care Medicine</i> , 2005, 33, 1603-1609.	0.4	175
237	Factors Associated with Outcome after Hemispherectomy for Large Middle Cerebral Artery Territory Infarction. <i>Neurosurgery</i> , 2005, 56, 681-692.	0.6	104
238	Surgery for primary supratentorial brain tumors in the United States, 1988 to 2000: The effect of provider caseload and centralization of care. <i>Neuro-Oncology</i> , 2005, 7, 49-63.	0.6	133
239	Craniotomy for meningioma in the United States between 1988 and 2000: decreasing rate of mortality and the effect of provider caseload. <i>Journal of Neurosurgery</i> , 2005, 102, 977-986.	0.9	103
240	Extracranial-intracranial bypass in the treatment of occlusive cerebrovascular disease and intracranial aneurysms in the United States between 1992 and 2001: a population-based study. <i>Journal of Neurosurgery</i> , 2005, 103, 794-804.	0.9	90
241	Synthesizing medical evidence: systematic reviews and metaanalyses. <i>Neurosurgical Focus</i> , 2005, 19, 1-21.	1.0	35
242	Adult-Born and Preexisting Olfactory Granule Neurons Undergo Distinct Experience-Dependent Modifications of their Olfactory Responses In Vivo. <i>Journal of Neuroscience</i> , 2005, 25, 10729-10739.	1.7	192
243	Case 5-2004. <i>New England Journal of Medicine</i> , 2004, 350, 707-716.	13.9	3
244	Achieving Normothermia in Patients With Febrile Subarachnoid Hemorrhage: Feasibility and Safety of a Novel Intravascular Cooling Catheter. <i>Neurocritical Care</i> , 2004, 1, 145-156.	1.2	41
245	Age-dependent Differences in Short-term Outcome after Surgical or Endovascular Treatment of Unruptured Intracranial Aneurysms in the United States, 1996-2000. <i>Neurosurgery</i> , 2004, 54, 18-30.	0.6	140
246	RESULTS OF A PROSPECTIVE PROTOCOL OF COMPUTED TOMOGRAPHIC ANGIOGRAPHY IN PLACE OF CATHETER ANGIOGRAPHY AS THE ONLY DIAGNOSTIC AND PRETREATMENT PLANNING STUDY FOR CEREBRAL ANEURYSMS BY A COMBINED NEUROVASCULAR TEAM. <i>Neurosurgery</i> , 2004, 54, 1329-1342.	0.6	210
247	Effect of Clipping, Craniotomy, or Intravascular Coiling on Cerebral Vasospasm and Patient Outcome after Aneurysmal Subarachnoid Hemorrhage. <i>Neurosurgery</i> , 2004, 55, 779-789.	0.6	115
248	Genetic and Cellular Therapies for Cerebral Infarction. <i>Neurosurgery</i> , 2004, 55, 283-297.	0.6	21
249	Hemispherectomy for Massive Cerebral Infarction. <i>Topics in Stroke Rehabilitation</i> , 2004, 11, 7-11.	1.0	2
250	Preliminary experience with intra-arterial nicardipine as a treatment for cerebral vasospasm. <i>American Journal of Neuroradiology</i> , 2004, 25, 819-26.	1.2	145
251	Surgical Excision of Acoustic Neuroma: Patient Outcome and Provider Caseload. <i>Laryngoscope</i> , 2003, 113, 1332-1343.	1.1	97
252	Microvascular Decompression Surgery in the United States, 1996 to 2000: Mortality Rates, Morbidity Rates, and the Effects of Hospital and Surgeon Volumes. <i>Neurosurgery</i> , 2003, 52, 1251-1262.	0.6	248

#	ARTICLE	IF	CITATIONS
253	Subarachnoid hemorrhage without evident cause on initial angiography studies: diagnostic yield of subsequent angiography and other neuroimaging tests. <i>Journal of Neurosurgery</i> , 2003, 98, 1235-1240.	0.9	100
254	In-hospital Mortality and Morbidity after Surgical Treatment of Unruptured Intracranial Aneurysms in the United States, 1996-2000: The Effect of Hospital and Surgeon Volume. <i>Neurosurgery</i> , 2003, 52, 995-1009.	0.6	85
255	Stratification of Outcome for Surgically Treated Unruptured Intracranial Aneurysms. <i>Neurosurgery</i> , 2003, 52, 82-88.	0.6	83
256	Important Factors for a Combined Neurovascular Team to Consider in Selecting a Treatment Modality for Patients with Previously Clipped Residual and Recurrent Intracranial Aneurysms. <i>Neurosurgery</i> , 2003, 52, 732-739.	0.6	46
257	In-hospital Mortality and Morbidity after Surgical Treatment of Unruptured Intracranial Aneurysms in the United States, 1996-2000: The Effect of Hospital and Surgeon Volume. <i>Neurosurgery</i> , 2003, 52, 995-1009.	0.6	51
258	In-hospital morbidity and mortality after endovascular treatment of unruptured intracranial aneurysms in the United States, 1996-2000: effect of hospital and physician volume. <i>American Journal of Neuroradiology</i> , 2003, 24, 1409-20.	1.2	122
259	In-hospital mortality and morbidity after surgical treatment of unruptured intracranial aneurysms in the United States, 1996-2000: the effect of hospital and surgeon volume. <i>Neurosurgery</i> , 2003, 52, 995-1007; discussion 1007-9.	0.6	101
260	Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 7009-7014.	3.3	116
261	Risk of Hemorrhage from Unsecured, Unruptured Aneurysms during and after Hypertensive Hypervolemic Therapy. <i>Neurosurgery</i> , 2002, 50, 1207-1212.	0.6	1
262	Proposed Use of Prophylactic Decompressive Craniectomy in Poor-grade Aneurysmal Subarachnoid Hemorrhage Patients Presenting with Associated Large Sylvian Hematomas. <i>Neurosurgery</i> , 2002, 51, 117-124.	0.6	170
263	Results of Multimodality Treatment for 141 Patients with Brain Arteriovenous Malformations and Seizures: Factors Associated with Seizure Incidence and Seizure Outcomes. <i>Neurosurgery</i> , 2002, 51, 303-311.	0.6	137
264	Risk of Hemorrhage from Unsecured, Unruptured Aneurysms during and after Hypertensive Hypervolemic Therapy. <i>Neurosurgery</i> , 2002, 50, 1207-1212.	0.6	34
265	Medical management of increased intracranial pressure after spontaneous intracerebral hemorrhage. <i>Neurosurgery Clinics of North America</i> , 2002, 13, 335-338.	0.8	8
266	Results of multimodality treatment for 141 patients with brain arteriovenous malformations and seizures: factors associated with seizure incidence and seizure outcomes. <i>Neurosurgery</i> , 2002, 51, 303-9; discussion 309-11.	0.6	43
267	Results after Surgical and Endovascular Treatment of Paraclinoid Aneurysms by a Combined Neurovascular Team. <i>Neurosurgery</i> , 2001, 48, 78-90.	0.6	139
268	Results after Surgical and Endovascular Treatment of Paraclinoid Aneurysms by a Combined Neurovascular Team. <i>Neurosurgery</i> , 2001, 48, 78-90.	0.6	102
269	Combined surgical and endovascular techniques of flow alteration to treat fusiform and complex wide-necked intracranial aneurysms that are unsuitable for clipping or coil embolization. <i>Journal of Neurosurgery</i> , 2001, 95, 24-35.	0.9	112
270	Subarachnoid hemorrhage. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2001, 3, 429-439.	0.4	1

#	ARTICLE	IF	CITATIONS
271	Management Outcomes for Ruptured and Unruptured Aneurysms in the Elderly. <i>Neurosurgery</i> , 2000, 47, 827-833.	0.6	78
272	Factors Associated with Reintegration to Normal Living after Subarachnoid Hemorrhage. <i>Neurosurgery</i> , 2000, 46, 1326-1334.	0.6	123
273	A TVA Single-Chain Antibody Fusion Protein Mediates Specific Targeting of a Subgroup A Avian Leukosis Virus Vector to Cells Expressing a Tumor-Specific Form of Epidermal Growth Factor Receptor. <i>Journal of Virology</i> , 2000, 74, 9540-9545.	1.5	31
274	BIOLOGICAL AGGRESSIVENESS OF HEREDITARY PROSTATE CANCER: LONG-TERM EVALUATION FOLLOWING RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 1998, 160, 660-663.	0.2	69
275	A Proposed Comprehensive Grading System to Predict Outcome for Surgical Management of Intracranial Aneurysms. <i>Neurosurgery</i> , 1998, 42, 959-968.	0.6	156
276	BIOLOGICAL AGGRESSIVENESS OF HEREDITARY PROSTATE CANCER. <i>Journal of Urology</i> , 1998, , 660-663.	0.2	4
277	One-year Outcome after Decompressive Surgery for Massive Nondominant Hemispheric Infarction. <i>Neurosurgery</i> , 1997, 40, 1168-1176.	0.6	246
278	Temporary vessel occlusion for aneurysm surgery: risk factors for stroke in patients protected by induced hypothermia and hypertension and intravenous mannitol administration. <i>Journal of Neurosurgery</i> , 1996, 84, 785-791.	0.9	186
279	Hereditary Prostate Cancer: Epidemiologic and Clinical Features. <i>Journal of Urology</i> , 1993, 150, 797-802.	0.2	519
280	Mendelian inheritance of familial prostate cancer.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 3367-3371.	3.3	653
281	Sexual Function following Radical Prostatectomy: Influence of Preservation of Neurovascular Bundles. <i>Journal of Urology</i> , 1991, 145, 998-1002.	0.2	505
282	Epidemiologic evidence regarding predisposing factors to prostate cancer. <i>Prostate</i> , 1990, 16, 187-197.	1.2	142
283	Family history and the risk of prostate cancer. <i>Prostate</i> , 1990, 17, 337-347.	1.2	609
284	Allelic loss of chromosomes 16q and 10q in human prostate cancer.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990, 87, 8751-8755.	3.3	436